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For neurons, overexcitement is deadly. 
To avoid this, brain cells must sop up 
unneeded neurotransmitters from the 
synapse through membrane-bound 
transporters. If these transporters fail, 
neurons and other brain cells get excited 
to death—a phenomenon that may con-
tribute to brain damage during stroke 
and Alzheimer’s disease.
Indeed, brain deterioration after 
stroke is associated with elevated levels 
of glutamate—the major excitatory 
neurotransmitter in the mammalian 
central nervous system (CNS)—in the 
plasma and cerebral spinal fluid. One 
possible explanation for this glutamate 
build-up, reported by Mallolas and 
colleagues on page  <ArtRef vol=”203” Iss=”3”><ArtRef vol=”203” Iss=”3”>711</ArtRef></ArtRef>, is a mutation in 
the gene encoding the glutamate trans-
porter protein EAAT2.
This mutation—a single adenine (A) 
to cytosine (C) change in the EAAT2 
promoter—was equally prevalent in 
healthy individuals and stroke patients. 
But among stroke patients, those with 
the mutated C allele had higher plasma 
levels of glutamate and were more likely 
to suffer from post-stroke neurological 
problems than those with the A allele.
The A-to-C mutation changed a 
binding site for the activating transcrip-
tion factor AP-2 into a binding site for 
the repressor GCF2—a swap that inhib-
ited promoter activity in transfected rat 
brain cells. Whether the mutant pro-
moter decreases EAAT2 expression in 
the human brain, as would be predicted, 
remains to be tested. 
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Blood clots are needed to patch vessel injuries. But clot size 
must be carefully controlled, as oversized clots (thrombi) 
can plug up blood vessels. The combined action of protease 
inhibitors, which inactivate clotting factors, and fibrin-
cleaving enzymes, which dissolve the fibrin meshwork of the 
clot, keeps clot size in check. On page  <ArtRef vol=”203”  Iss=”3”><ArtRef vol= ”203” Iss=”3”>767</ArtRef></ArtRef>, Chauhan and 
colleagues find that another enzyme—the metalloprotease 
ADAMTS13—is also required to limit clot size.
ADAMTS13 chops up ultra-large multimers of von 
Willebrand factor (UL-VWF), the blood protein that tethers 
platelets to injured blood vessels. The importance of dicing 
up UL-VWF became clear when defects in ADAMTS13 were 
identified as the cause of the life-threatening disease 
thrombotic thrombocytopenic purpura (TTP). In patients 
with TTP, small clots—composed largely of platelets and 
VWF—form in vessels, eventually breaking free and clogging 
downstream vessels. What instigates clot formation in 
these patients is unknown, although infections are often 
associated with the onset of TTP symptoms.
A collaborating group recently created a mouse model 
of TTP by making mice that lack ADAMTS13. In these mice, newly released UL-VWF remained stuck to the 
vessel wall for longer than normal, snaring passing platelets and forming long strings that wave in the 
bloodstream. When injected with a vessel-damaging bacterial toxin, the ADAMTS13-deficient mice 
developed a TTP-like disease, with unstable VWF platelet–rich clots forming in their veins.
Now, Chauhan and colleagues show that ADAMTS13 not only inhibits the initial adhesion of platelets 
to the vessel wall, but also limits the growth of platelet-containing clots. In the deficient mice, 
spontaneous clots formed and injury-induced clots grew larger and faster than in normal mice. Treating 
the mice with recombinant ADAMTS13 dissolved injury-induced clots, suggesting that ADAMTS13’s clot-
busting power could potentially be harnessed for the treatment of thrombotic conditions such as heart 
attacks and strokes. 
Vessel-plugging clots (arrow) form in mice lacking the protease ADAMTS13.
A mutation in the promoter region of the gene 
encoding the glutamate transporter EAAT2 
is associated with increased neurological 
deterioration after stroke.